
Feature|Articles|December 1, 2025
FDA updates in urology: November 2025
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from November 2025.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! November was a busy month for regulatory news in urology, with several key approvals and several more agents coming down the pike. This month’s notable advances included the removal of the “black box” warning label on hormone replacement therapy, as well as the approval of pembrolizumab (Keytruda) plus enfortumab vedotin-ejfv (Padcev) for patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.
Related to this article

Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.

The phase 1/2 ARGATE-001 trial will assess the safety, tolerability, and preliminary efficacy of EIK1006 in patients with metastatic androgen pathway modulation-resistant prostate cancer.

Moderators in 4 forums reviewed ARANOTE, ARACOG, and ARASEC data and discussed what differentiates doublet options in mCSPC.

CG Oncology plans to submit a second biologics license application to the FDA for cretostimogene in BCG-unresponsive NMIBC by the end of March 2027

Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
Advertisement
Advertisement



